Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia
NCT ID: NCT02975973
Last Updated: 2020-11-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2016-11-30
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In summary, a successful outcome of this study would provide tDCS the sound mechanistic and methodologic basis for more definitive testing in large-scale clinical trials as a highly innovative therapeutic intervention for cognitive impairments in schizophrenia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2.5mA
Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
transcranial direct current stimulation
transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
2.0mA
Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
transcranial direct current stimulation
transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
1.5mA
Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
transcranial direct current stimulation
transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
0mA
This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
transcranial direct current stimulation
transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
transcranial direct current stimulation
transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. within first five years of antipsychotic treatment;
3. on stable doses of antipsychotic medication for at least one month;
4. Clinically stable as defined by Clinical Global Impression-Severity scale (CGI-S) less than or equal to 4 (moderately ill);
5. Mild to severe cognitive impairment in MATRICS Consensus Cognitive Battery (composite scores \<40);
6. DSM-5 MINI 7.0.2 criteria for schizophrenia or schizoaffective by patient SCID
Exclusion Criteria
2. significant head injury;
3. History of severe medical or neurological illnesses
4. pregnancy or postpartum (\<6 weeks after delivery or miscarriage);
5. inability to provide informed consent;
6. significant color blindness that affects task performance;
7. Positive urine drug screen (exception for marijuana) or presence of substance use disorder within 1 month;
8. Currently on benzodiazepines or mood stabilizers affecting GABA
18 Years
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Baylor College of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Raymond Cho
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raymond Cho, M.D., M.Sc.
Role: PRINCIPAL_INVESTIGATOR
Baylor College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baylor College of Medicine
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-41815
Identifier Type: -
Identifier Source: org_study_id